A phase i Bayesian adaptive design to simultaneously optimize dose and schedule assignments both between and within patients

Journal of the American Statistical Association

Volumn 108, Issue 503, 2013, Pages 892-901

  Zhang, Jin ^a   Braun, Thomas M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bayesian statistics; Clinical trial; Dose escalation study; Dynamic treatment regime; Nonmixture cure model

Indexed keywords

EID: 84890098695     PISSN: 01621459     EISSN: 1537274X     Source Type: Journal    
DOI: 10.1080/01621459.2013.806927     Document Type: Article

References (17)

1. Babb, J., Rogatko, A., and Zacks, S. (1998), "Cancer Phase I Clinical Trials: Efficient Dose Escalation With Overdose Control, " Statistics in Medicine, 17, 1103-1120. [895].
2. Braun, T. M. (2005), "Generalizing the TITE-CRM to Adapt for Early-and Late-Onset Toxicities, " Statistics in Medicine, 20, 153-169. [893].
3. Braun, T. M., Thall, P. F., Nguyen, H., and de Lima, M. (2007), "Simultaneously Optimizing Dose and Schedule of a New Cytotoxic Agent, " Clinical Trials, 4, 113-124. [892,897].
4. Braun, T. M., Yuan, Z., and Thall, P. F. (2005), "Determining a Maximum-Tolerated Schedule of a Cytotoxic Agent, " Biometrics, 61, 335-343. [892].
5. Chen, M., Ibrahim, J., and Sinha, D. (1999), "A New Bayesian Model for Survival Data With a Surviving Fraction, " Journal of American Statistical Association, 94, 909-919. [893,894].
6. Cheung, Y. K., and Chappell, R. (2000), "Sequential Designs for Phase I Clinical Trials With Late-Onset Toxicity, " Biometrics, 56, 1177-1182. [893].
7. de Lima, M., Giralt, S., Thall, P. F., Silva, L., Jones, R. B., Komanduri, K., Braun, T. M., Nguyen, H. Q., Champlin, R., and Garcia-Manero, G. (2010), "Maintenance TherapyWith Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent AcuteMyelogenous Leukemia or Myelodysplastic Syndrome: A Dose and Schedule Finding Study, " Cancer, 116, 5420-5431. [892].
8. Hougaard, P. (2000), Analysis of Multivariate Survival Data, New York: Springer. [894].
9. Liu, C., and Braun, T. M. (2009), "Parametric Non-Mixture Cure Models for Schedule Finding of Therapeutic Agents, " Journal of the Royal Statistical Society, Series C, 58, 225-236. [892,893,895].
10. Murphy, S. A. (2003), "Optimal Dynamic Treatment Regimes, " Journal of the Royal Statistical Society, Series B, 65, 331-336. [901].
11. O'Quigley, J., Pepe, M., and Fisher, L. (1990), "Continual Reassessment Method: A Practical Design for Phase I Clinical Trials in Cancer, " Biometrics, 46, 33-48. [893].
12. Raftery, A. E., Madigan, D., and Hoeting, J. A. (1997), "Bayesian Model Averaging for Linear Regression Models, " Journal of the American Statistical Association, 92, 179-191. [893].
13. Rosenthal, J. (2007), "AMCMC: An R Interface for Adaptive MCMC, " Computational Statistics and Data Analysis, 51, 5467-5470. [894].
14. Tsiatis, A. (1975), "A Nonidentiability Aspect of the Problem of Competing Risks, " Proceedings of the National Academy of Sciences in USA, 72, 20-22. [894].
15. Tsodikov, A., Ibrahim, J., and Yakovlev, A. (2003), "Estimating Cure Rates From Survival Data: An Alternative to Two-Component Mixture Models, " Journal of American Statistical Association, 98, 1063-1078. [893].
16. Yin, G., and Yuan, Y. (2009), "Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials, " Journal of the American Statistical Association, 104, 954-972. [893].
17. Yuan, Y., and Yin, G. (2009), "Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy as Time-to-Event Outcomes, " Journal of the Royal Statistical Society, Series C, 58, 719-736. [901].